May 19, 2025
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically
American Thoracic Society (ATS) 2025
Read More
May 17, 2025
Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
October 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More
September 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
European Academy of Dermatology and Venereology (EADV) 2024
Read More
May 22, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma
American Thoracic Society (ATS) 2024
Read More
May 21, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model
Digestive Disease Week (DDW) 2024
Read More
March 8, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More